Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ex-JPMA Chief Aoki Wants to See Japan’s Gilead, Govt Leadership in Consolidation
July 3, 2017
- Takeda Puts Up 2.75 Billion Yen for Health Programs in Developing Nations
July 3, 2017
- Mirogabalin Hits Primary Endpoint in Post-Herpetic Neuralgia: Daiichi Sankyo
July 3, 2017
- Astellas Files US sNDA for Myrbetriq-Vesicare Combo Use
July 3, 2017
- Kyowa Kirin Launches Japan PIII Trial on Mogamulizumab for HTLV-1-Associated Myelopathy
July 3, 2017
- Nippon Kayaku Prevails in Elplat Damage Suit: High Court
June 30, 2017
- Takeda Files Teva’s Parkinson’s Disease Med in Japan
June 30, 2017
- Weber’s FY2016 Pay Tops 1 Billion Yen: Takeda Securities Filing
June 30, 2017
- Oncolys to Initiate PI Trial of Oncolytic Virus Telomelysin “Shortly” in Japan
June 30, 2017
- Takeda Chairman Hasegawa Officially Steps Aside as Adviser
June 29, 2017
- Eisai Temporarily Rescinds NDA for Halaven in China due to Request for Additional Data
June 29, 2017
- Adcetris Hits Primary Endpoint in PIII Trial for Frontline Advanced Hodgkin’s Lymphoma: Takeda, Seattle Genetics
June 29, 2017
- AbbVie Japan Set to Build Up Organization to Gear Up for Oncology Drug Launches: President
June 28, 2017
- Drug Makers Moving to Outsource “Pharmaceutical Scouting” to Seek Efficiency: Ex-Sanofi Exec
June 28, 2017
- Stivarga OK’ed for 2nd-Line HCC, Oldamin for Gastric Varices, Actemra for Shorter Dose Interval
June 27, 2017
- Takeda in Technology Licensing Deals with Biological E. for Low-Cost Vaccines
June 27, 2017
- Immuno-Biological Laboratories, TransGenic Collaborate on AD Drug Research
June 27, 2017
- Keytruda Earns Priority Review Status for Urothelial Cancer
June 27, 2017
- Pfizer Japan Oncology Unit Creates Growth Strategy, Portfolio Priority Map to Gear Up for Doubling of Products
June 27, 2017
- Pfizer Japan Ups Oncology Sales Force, Reorganizes It into Blood, Solid Cancer Groups
June 27, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…